Sanofi's multiple sclerosis drug, previously rejected by FDA, receives positive recommendation from European regulators

Sanofi's multiple sclerosis drug, which the U.S. FDA turned down late last year, has now been reviewed by European authorities.

The European regulators issued a positive recommendation today, suggesting the medicine should be approved for use in the region.

The development offers a potential new treatment option for multiple sclerosis patients in Europe and may influence future regulatory discussions, though the drug still awaits formal approval.